Rosiglitazone induced an increase in both of DUSP1 and DUSP5; while metformin, a first-line treatment for type 2 diabetes, enhanced DUSP5 expression (Figure 5; Supplementary Table S2). Here, DUSP5 is linked to type 2 diabetes mellitus.